<DOC>
	<DOCNO>NCT01852890</DOCNO>
	<brief_summary>This phase 1 ( first man ) study test safety add high dose ascorbate ( vitamin C ) standard radiation chemotherapy treatment pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine , Ascorbate , Radiation Therapy Pancreatic Cancer , Phase I</brief_title>
	<detailed_description>This phase 1 study test safety add high dose ascorbate ( vitamin C ) standard chemoradiation . The ascorbate infuse external beam radiation therapy treatment . For patient eligible trial , standard treatment cancer include radiation therapy combine weekly gemcitabine ( chemotherapy ) . Participants : - receive high dos intravenous ( IV ) ascorbate daily radiation therapy treatment . Radiation treatment give day , Monday Friday . - routine doctor 's visit ask side effect experience . This phase 1 study evaluate side effect add ascorbate standard therapy . The dose give participant determine well participant tolerate ascorbate .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Patients must histologically cytologically diagnose pancreatic adenocarcinoma . Documentation disease extent CT scan require . Radiologically measurable disease require . Age ≥ 18 year ECOG performance status 0 , 1 , 2 ( Karnofsky &gt; 50 % ) . A complete blood count differential must obtain within 21 day prior radiation fraction 1 , adequate bone marrow function define : Absolute neutrophil count ( ANC ) ≥ 1500 cell per mm3 Platelets ≥ 100,000 per mm3 Leukocytes ≥ 3,000 per mm3 Serum blood chemistry within 21 day radiation fraction 1 , define : Creatinine ≤ 1.5 x UIHC upper limit normal creatinine clearance least 60 ml/min/1.73 m2 patient creatinine level institutional normal . Total bilirubin ≤ 2 x UIHC upper limit normal ALT ≤ 2.5 time UIHC upper limit normal AST ≤ 2.5 time UIHC upper limit normal PT/INR within normal limit ( UIHC ) Tolerate one test dose ( 15g ) ascorbate . Not pregnant . Ability understand willingness sign write informed consent document . G6PD ( glucose6phosphate dehydrogenase ) deficiency . Prior abdominal radiotherapy would result overlap field . The treat radiation oncologist review prior RT field available . Adjuvant therapy ( include radiation therapy ) within 2 calendar week . Toxicities prior therapy malignancy resolve grade 1 less . Patients actively receive insulin exclude . Patients follow drug drug substitution : flecainide , methadone , amphetamine , quinidine , chlorpropamide . High dose ascorbate may affect urine acidification , result , may affect clearance rate drug . Second malignancy nonmelanoma skin cancer within past 5 year . Other investigational agents/therapy intention treat disease study ( observational imaging trial acceptable ) . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation , condition would limit compliance study requirement determine study team member . Pregnant lactating woman : The risk radiation chemotherapy fetus well document . Known HIVpositive individual . Highdose ascorbate acid know CYP450 3A4 inducer , result low serum level antiretroviral drug . A clinical trial design address interaction issue appropriate phase 1 study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ascorbate</keyword>
	<keyword>Vitamin C</keyword>
	<keyword>Radiation</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Ascorbic Acid</keyword>
</DOC>